References
Volkow ND, Baler RD, Compton WM et al. (2014) Adverse health effects of marijuana use. N Engl J Med 370(23):2219–2227. https://doi.org/10.1056/NEJMra1402309
Health Products Regulatory Authority (2017) Cannabis for medical use—a scientific review. Ireland
Vujcic I, Pavlovic A, Dubljanin E, Maksimovic J, Nikolic A, Sipetic-Grujicic S (2017) Attitudes toward medical cannabis legalization among Serbian medical students. Subst Use Misuse 52(9):1225–1231. https://doi.org/10.1080/10826084.2017.1302959
Newton-Howes G (2017) Cannabis as medicine. BMJ 357. https://doi.org/10.1136/bmj.j2130
Barrett P, Bradley C (2016) Attitudes and perceived risk of cannabis use in Irish adolescents. Ir J Med Sci 185(3):643–647. https://doi.org/10.1007/s11845-015-1325-2
Andreae MH, Rhodes E, Bourgoise T, Carter GM, White RS, Indyk D, Sacks H, Rhodes R (2016) An ethical exploration of barriers to research on controlled drugs. Am J Bioeth 16(4):36–47. https://doi.org/10.1080/15265161.2016.1145282
Vasconcelos SC, Silva AO, Moreira M et al (2017) Bioethical analysis to the therapeutic use of Cannabis: integrative review. Nurs Ethics 969733017703699. https://doi.org/10.1177/0969733017703699
Whiting PF, Wolff RF, Deshpande S, di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313(24):2456–2473. https://doi.org/10.1001/jama.2015.6358
Devinsky O, Cross JH, Wright S, Cannabidiol in Dravet Syndrome Study Group (2017) Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 376(21):2011–2020. https://doi.org/10.1056/NEJMoa1611618
Berkovic SF (2017) Cannabinoids for epilepsy-real data, at last. N Engl J Med 376(21):2075–2076. https://doi.org/10.1056/NEJMe1702205
Ammerman S, Ryan S, Adelman WP (2015) The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics 135(3):e769–e785. https://doi.org/10.1542/peds.2014-4147
Flemming K (2010) The use of morphine to treat cancer-related pain: a synthesis of quantitative and qualitative research. J Pain Symptom Manag 39(1):139–154. https://doi.org/10.1016/j.jpainsymman.2009.05.014
Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, von Korff M (2010) Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 152(2):85–92. https://doi.org/10.7326/0003-4819-152-2-201001190-00006
U.S. Department of Drug Administration (2018) Controlled Substances Act. U.S. Department of Drug Administration. https://www.dea.gov/druginfo/csa.shtml. Accessed 7 February 2018
Department of Health (2018) Misuse of drugs legislation. Department of Health. https://www.health-ni.gov.uk/articles/misuse-drugs-legislations. Accessed 7 February 2018
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
O’Doherty, J., O’Connor, R. The case for medicinal cannabis. Ir J Med Sci 187, 539–540 (2018). https://doi.org/10.1007/s11845-018-1770-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-018-1770-9